1. Home
  2. >>Pink Sheet
  3. >>Conferences
  4. >>AAM

AAM

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

 
• By Dave Wallace

With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – says that the US biosimilars market is ‘doing better, but we still have improvements to make.’

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

 
• By Dave Wallace

With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is ‘doing better, but we still have improvements to make.’